biomedicines

IMPACT FACTOR 4.7

Indexed in: PubMed

CITESCORE 3.7

an Open Access Journal by MDPI

Diagnosis, Pathogenesis and Treatment of Muscular Dystrophy

Guest Editor:

Dr. Manuela Bozzi
Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Sezione di Biochimica e Biochimica Clinica, Università Cattolica del Sacro Cuore, Rome, Italy

Deadline for manuscript submissions:
closed (30 April 2024)

Message from the Guest Editor

The purpose of this Special Issue, "Diagnosis, Pathogenesis and Treatment of Muscular Dystrophy", is to publish research and review articles that address the topic of Muscular Dystrophies (MDs) from different points of view.

Authors are invited to contribute to this Special Issue with studies that explore the biochemical mechanisms leading to the degeneration of skeletal muscle and to metabolic dysfunction, which is often associated to several forms of MD. Particularly welcome are articles that pave the way for the development of therapeutic interventions that aim to restore the normal muscle phenotype and function. This Special Issue will also offer insight into innovative diagnostic tools, including the identification of new molecular markers, which is useful for an early and non-invasive diagnosis. Potential topics include, but are not limited to:

- Skeletal muscle tissue regeneration, homeostasis and repair;
- Metabolic dysfunctions in muscular dystrophy;
- Autophagy/mitophagy in muscular dystrophy;
- The development of therapeutic protocols for muscular dystrophy;
- Biomarkers in muscular dystrophy.

biomedicines

IMPACT FACTOR 4.7 | Indexed in: PubMed | CITESCORE 3.7

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI